Last reviewed · How we verify
NCT06883305: EMBARK
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Phase 3 trial testing Tezepelumab in Chronic Obstructive Pulmonary Disease (COPD) in 990 participants. Currently enrolling.
13 March 2029
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 990 |
| Start date | 18 March 2025 |
| Primary completion | 13 March 2029 |
| Estimated completion | 5 June 2029 |
| Sites | 298 locations across Denmark, Italy, Slovakia, Malaysia, India, Chile, United Kingdom, Germany |
Drugs / interventions tested
- Tezepelumab (TEZEPELUMAB) — full drug profile →
- Placebo
Conditions studied
- Chronic Obstructive Pulmonary Disease (COPD) — all drugs for Chronic Obstructive Pulmonary Disease (COPD) →
Sponsor
AstraZeneca — full company profile →
Who can join
Adults 40 to 80, any sex, with Chronic Obstructive Pulmonary Disease (COPD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets.
Fricker M, Lokwani R. · · 2025 · cited 2× · PMID 41124071 · DOI 10.1042/cs20255452 -
Emerging Systemic Treatments for Asthma and Allergic Diseases: New Tricks, Same Dog?
Tomasello A, Szefler SJ, Cahill KN. · · 2026 · cited 2× · PMID 40912614 · DOI 10.1016/j.jaip.2025.08.022 -
Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.
Mari PV, Carriera L, Ielo S, Di Michele L, et al · · 2026 · PMID 41989656 · DOI 10.1007/s11882-026-01271-8 -
Biomarker understanding first lessons from drug development for IgA-driven autoimmune and fibrotic diseases
van Delft M, Cegiel A, van Egmond M, Boon L. · · 2025 -
Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice recommendations.
Chen Y, Yang T, Zhang J, Chen X, et al · · 2025 · PMID 41551016 · DOI 10.1016/j.pccm.2025.11.004 -
Immunotherapies for Aging and Age-Related Diseases: Advances, Pitfalls, and Prospects.
Yang M, Wu S, Zhang J, Lu L, et al · · 2025 · PMID 40927754 · DOI 10.34133/research.0866
Verify or expand the search:
- PubMed search for NCT06883305
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tezepelumab
Trials testing the same drug.
- NCT07520162 — A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab · Phase 3 · not yet recruiting
- NCT07015996 — Efficacy of Tezepelumab in Peanut Oral Immunotherapy · Phase 2 · not yet recruiting
- NCT07363642 — Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab · Phase 3 · recruiting
- NCT07046117 — Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis · NA · not yet recruiting
- NCT06951867 — Tezspire Cardiac Events PASS · recruiting
Other recruiting trials for Chronic Obstructive Pulmonary Disease (COPD)
Currently open trials in the same condition.
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07355868 — Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy · EARLY_PHASE1 · recruiting
- NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
- NCT06892210 — Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) · Phase 4 · recruiting
- NCT07519603 — Frailty in Older Adults With Chronic Obstructive Pulmonary Disease (COPD) and Outcomes of the VIVIFRAIL Program · NA · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06883305 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06883305.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing